COMMUNIQUÉS West-GlobeNewswire

Press Release: Tzield approved in China as first disease-modifying therapy for adult and pediatric patients with stage 2 type 1 diabetes
10/09/2025
Tzield approved in China as first disease-modifying therapy for adult and pediatric patients with stage 2 type 1 diabetes Approval based on the TN-10 study, demonstrating Tzield’s ability to delay the onset of stage 3 [...]
Communiqué de presse : Tzield approuvé en Chine comme premier traitement modificateur de la maladie pour les patients adultes et pédiatriques atteints de diabète de type 1 au stade 2
10/09/2025
Tzield approuvé en Chine comme premier traitement modificateur de la maladie pour les patients adultes et pédiatriques atteints de diabète de type 1 au stade 2 Approbation basée sur l’étude TN-10, qui démontre la [...]
Pharming Group promoted to the Euronext AMX® index
10/09/2025
Leiden, the Netherlands, September 10, 2025: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext: PHARM; Nasdaq: PHAR) today announced that it has been promoted from the Euronext AScX® (Small Cap) to the AMX® ( [...]
Bioversys Reports Corporate Highlights and Key Financials For the First Half 2025
10/09/2025
BV100: successful end of Phase 2 meeting with US FDA following Positive Phase 2 read-out in Ventilator-Associated Bacterial Pneumonia (VABP); Phase 3 on track to initiate in 2025; Formulation patent granted in China, [...]
Dianthus Therapeutics, Inc. Announces Pricing of Upsized $251 Million Underwritten Public Offering
10/09/2025
NEW YORK and WALTHAM, Mass., Sept. 09, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement [...]
Rapport Announces Pricing of Public Offering of Common Stock
10/09/2025
BOSTON and SAN DIEGO, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery and development of small [...]
Telix Doses First Patient in Phase 3 BiPASS Trial: PSMA-PET Imaging for Prostate Cancer Diagnosis
10/09/2025
MELBOURNE, Australia and INDIANAPOLIS, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces it has dosed the first patient in a Phase 3 clinical trial aimed [...]
Significant Breakthrough! eefit Far Infrared Technology Improves Two Major Symptoms of Alzheimer’s Disease, Bringing New Hope to Brain Health Protection
09/09/2025
Hong Kong, Sept. 09, 2025 (GLOBE NEWSWIRE) -- With Hong Kong’s aging population, Alzheimer’s disease has become a major public health challenge. The Hong Kong Council of Social Service projects that by 2036, the number [...]
Actuate Therapeutics Announces Proposed Public Offering of Common Stock
09/09/2025
CHICAGO and FORT WORTH, Texas, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for [...]
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities
09/09/2025
ZUG, Switzerland, Sept. 09, 2025 (GLOBE NEWSWIRE) -- The attached notifications relate to the vesting and settlement of RSUs previously granted to directors of the Company. Attachments Notification of managers' [...]
Iridex Corporation Receives Formal Notification of Nasdaq Listing Compliance
09/09/2025
MOUNTAIN VIEW, Calif., Sept. 09, 2025 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for [...]
Picard Medical, Inc. Announces Exercise of Underwriters’ Over-Allotment Option in Connection with its Initial Public Offering
09/09/2025
TUCSON, Ariz., Sept. 09, 2025 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: PMI) (“Picard” or the “Company”), today announced that the underwriters of its previously announced initial public offering of [...]
InnovAge Announces Financial Results for the Fourth Quarter and Fiscal Year Ended June 30, 2025
09/09/2025
DENVER, Sept. 09, 2025 (GLOBE NEWSWIRE) -- InnovAge Holding Corp. (“InnovAge” or the “Company”) (Nasdaq: INNV), an industry leader in providing comprehensive healthcare programs to frail, predominantly dual-eligible [...]
Celcuity Announces Upsized Senior Secured Term Loan Facility of $500 Million with Innovatus Capital Partners and Oxford Finance
09/09/2025
MINNEAPOLIS, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (“Celcuity”), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that it has entered into an [...]
CRISPR Therapeutics to Present Late-Breaking Data at the American Heart Association (AHA) Scientific Sessions 2025
09/09/2025
ZUG, Switzerland and BOSTON, Sept. 09, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today [...]
Serina Therapeutics Secures Up to $20 Million to Advance Registrational Trial of SER-252 in Parkinson’s Disease
09/09/2025
Transaction structured to provide flexible funding to support Phase 1b registrational clinical study program in advanced Parkinson’s under the 505(b)(2) NDA pathway Evaluating complementary funding including strategic [...]
Tevogen Estimates 5-Year Top-Line Revenue of ∼$6.5 Billion For Product Focused on Liver Cancer Prevention with High-Risk Chronic Hepatitis B Infection
09/09/2025
Risk adjusted Net Present Value (rNPV) for TVGN 116 is estimated to exceed ~$325 million in the US alone. WARREN, N.J., Sept. 09, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN [...]
KFSHRC Concludes Strategic Role at C3 Davos of Healthcare New York Summit
09/09/2025
NEW YORK, Sept. 09, 2025 (GLOBE NEWSWIRE) -- King Faisal Specialist Hospital & Research Centre (KFSHRC) concluded its participation as Strategic Partner and strategic partner of the C3 Davos of Healthcare™ New York [...]
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
09/09/2025
Company Announcement COPENHAGEN, Denmark; September 9, 2025 – Genmab A/S (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document [...]

Pages